GO
Loading...

Drugs

More

  • What new GSK cancer deal shows about pharma market Monday, 2 Jun 2014 | 3:33 AM ET

    The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.

  • Immunotherapies hit ASCO  Thursday, 29 May 2014 | 3:35 PM ET

    This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.

  • GSK invites private equity bid for drugs: Sources Thursday, 29 May 2014 | 12:34 PM ET
    A GlaxoSmithKline Plc logo sits on a sign outside the company's headquarters in London, U.K.

    GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.

  • Ataluren drives PTC Therapeutics  Friday, 23 May 2014 | 10:25 AM ET

    CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.

  • Pfizer: A deal to dodge the tax man in America Tuesday, 13 May 2014 | 2:28 AM ET

    Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.

  • Resolving drug issue will boost Colombia: Fin Min  Monday, 5 May 2014 | 7:00 PM ET

    Colombian Finance Minister Mauricio Cárdenas Santamaria says resolving the country's drugs issue will help the country post stronger growth.

  • Biogen barreling down on Alzheimer's  Wednesday, 23 Apr 2014 | 3:33 PM ET

    CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.

  • Investor pressure pushing drugmaker M&A deals Wednesday, 23 Apr 2014 | 6:11 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.

  • On a high: Hemp to boost US economy?  Wednesday, 16 Apr 2014 | 11:40 AM ET

    The hemp industry could become one of the U.S.'s biggest now its industrial use had been legalized, says Doug Fine, author of "Hemp Bound".

  • Luis Videgaray, finance minister of Mexico, says the U.S. must "share responsibility" for tackling drug cartels.

  • Pfizer CEO worries about ACA coverage  Thursday, 10 Apr 2014 | 11:43 AM ET

    Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.

  • Diversifying your pharma portfolio  Monday, 7 Apr 2014 | 1:07 PM ET

    Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.

  • Why this $84,000 drug costs just $900 abroad Saturday, 29 Mar 2014 | 2:29 PM ET

    Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."

  • 'Eye-opening' new report about statin eligibility Wednesday, 19 Mar 2014 | 5:06 PM ET
    Lipitor tablets

    Almost half of Americans ages 40 to 75 qualify to consider cholesterol-lowering statin drugs under new heart disease prevention guidelines.

  • The Zohydro debate: More harm than good?  Tuesday, 11 Mar 2014 | 3:20 PM ET

    Powerful new pain killer Zohydro, is prescribed to help people with chronic pain. Dr. Andrew Kolodny thinks the FDA has put out a drug that will kill people. Dr. Steven Garner, New York Methodist Hospital, thinks the drug will help many people who are suffering with lasting pain.

  • Controversial drug Zohydro here to stay?  Tuesday, 11 Mar 2014 | 1:00 PM ET

    CNBC's Sheila Dharmarajan discusses the new pain killer Zohydro which contains the same addictive elements as Oxycodone.

  • The go-to guy: A conversation with a drug dealer Wednesday, 26 Feb 2014 | 3:25 PM ET

    While out exploring marijuana's first legal frontier, CNBC took a moment to catch up with one young man who has stayed on the darker side of weed—the illegal side.

  • Dabs—marijuana's explosive secret Wednesday, 26 Feb 2014 | 12:37 PM ET
    Nicholas Broms, who was involved in a drug-related explosion last November. Broms was one of the growing number of casualties from manufacturing hash oil, a potent marijuana byproduct made with butane.

    From exploding kitchens to super-intense highs, making and smoking marijuana concentrate—aka “dabs”—is getting more attention in the move toward legalization.

  • Open Vape: The e-cigarette of legal pot Wednesday, 26 Feb 2014 | 12:12 PM ET

    Todd Mitchem's company, Open Vape, manufactures a product similar to an e-cigarette. It's a pen that heats a cartridge filled with purified cannabis oil.

  • Jane West: Wife, mother and 'potrepreneur' Tuesday, 25 Feb 2014 | 5:49 PM ET

    West, who lives in an affluent Denver suburb, calls herself "one part Martha Stewart and one part Walter White."